At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET
Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted by a significant reduction in net loss due to lower R&D spending following the completion of its pivotal lorundrostat trials. The company also announced FDA acceptance of its NDA for lorundrostat in hypertension, with a PDUFA date of December 22, 2026, marking a major regulatory milestone. Cash reserves increased to $656.6 million, sufficient to fund operations into 2028.
- FDA accepted NDA for lorundrostat with PDUFA target date of December 22, 2026
- Cash, cash equivalents, and investments totaled $656.6 million as of December 31, 2025, up from $198.2 million in 2024
- Net loss decreased to $154.7 million in 2025 from $177.8 million in 2024
- R&D expenses declined to $132.0 million in 2025 from $168.6 million in 2024 due to completion of pivotal trials
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access